GLSI — Greenwich LifeSciences, Inc. stock price, charts and financials

QT52Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. (NASDAQ: GLSI) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
18.99
+0.60+3.26%
OverviewShort InterestFilings
GLSIQT52Greenwich LifeSciences, Inc.·NASDAQ
18.99+3.26%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand14.68MPerf Week22.91%
Market Cap278.74MForward P/E-EPS next Y-1.17Insider Trans0.10%Shs Float7.38MPerf Month9.52%
Enterprise Value272.74MPEG-EPS next Q-0.34Inst Own-Short Float22.50%Perf Quarter-18.78%
Income-19.00MP/S0.00EPS this Y-Inst Trans-Short Ratio10.49Perf Half Y-26.62%
Sales0.00P/B72.47EPS next Y15.52%ROA-244.25%Short Interest1.66MPerf YTD-9.61%
Book/sh0.00P/C46.45EPS next 5Y-ROE-793.76%52W High34.10 -44.31%Perf Year70.31%
Cash/sh0.41P/FCF-EPS past 3/5Y-ROIC-701.55%52W Low7.78 144.09%Perf 3Y101.38%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility9.52% 8.72%Perf 5Y-58.82%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-4.13%Oper. Margin0.00%ATR (14)1.42Perf 10Y-
Dividend Ex-Date-Quick Ratio1.54Sales Y/Y TTM-Profit Margin0.00%RSI (14)63.54Recom2.00
Dividend Gr. 3/5Y-Current Ratio1.54EPS Q/Q-8.00%SMA2015.32%Beta1.41Target Price50.00
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5019.24%Rel Volume1.99Prev Close18.39
Employees13LT Debt/Eq-EarningsNov 13SMA200-11.57%Avg Volume151.32KPrice18.99
IPO DateSep 25, 2020Option/ShortYes / YesEPS/Sales Surpr.18.18% -Net Debt/EBITDA0.41Volume301,250Change3.26%
Analyst Ratings
DateActionAnalystRatingTarget
Dec-30-25ReiteratedHC Wainwright & Co.Buy$50
Latest News· Times ET
Aug-27-26
Aug-27-2612:48PM
20 stocks likely to lose money even if the bull market continuesmarketwatch.com
Aug-10-26
Aug-10-2602:07AM
Greenwich LifeSciences Extends 100% Insider Share Lock‑Up To January 31, 2027Benzinga
02:00AM
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027globenewswire.com
Jul-22-26
Jul-22-2602:00AM
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdomglobenewswire.com
Jul-21-26
Jul-21-2609:03AM
HC Wainwright & Co. Maintains Buy on Greenwich LifeSciences, Raises Price Target to $69Benzinga
Jul-20-26
Jul-20-2602:00AM
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01globenewswire.com
Jul-16-26
Jul-16-2603:31AM
Greenwich LifeSciences Receives Approval From European Medicines Agency To Combine HLA-A*02, Non-HLA-A*02 Participants In EuropeBenzinga
03:30AM
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01globenewswire.com
Jul-15-26
Jul-15-2611:33PM
Greenwich LifeSciences The Overlooked Needseekingalpha.com
Jul-09-26
Jul-09-2602:04AM
Greenwich LifeSciences Receives EMA Approval To Use Commercially Manufactured GP2 In Its FLAMINGO-01 Phase III Clinical TrialBenzinga
02:00AM
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01globenewswire.com
Company

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials. This drug is designed to prevent the recurrence of breast cancer in patients who have already undergone surgical removal of the tumor. Founded in 2006 and based in Stafford, Texas, the company was formerly known as Norwell, Inc. until it rebranded to Greenwich LifeSciences, Inc. in March 2018.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
FY 2017
12/31/2017
Total Revenue
000——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
000——————
Selling, General and Administrative Excl. Other222——————
Research and Development17158——————
Other Operating Expense01-1——————
Operating Income-19-18-9——————
Interest Expense
000——————
Unusual Expense
—————————
Non-Operating Income (Expense)
000——————
Net Income Before Taxes-19-17-9——————
Income Taxes
000——————
Consolidated Net Income-19-17-9——————
Net Income From Continuing Operations-19-17-9——————
Net Income-19-17-9——————
EPS (Recurring)-1.43-1.21-0.69——————
EPS (Basic, Before Extraordinaries)-1.43-1.21-0.69——————
EPS (Diluted)-1.43-1.21-0.69——————
EBITDA-19-17-9——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding141313——————
Market Capitalization294146137——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$37.43$29.07$20.71$12.35$3.99● Close Price0.00K51.65K103.30K154.96K206.61KUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Patel SnehalCEO and CFOJul 29 '26Buy13.107009,1705,611,402Jul 30
Patel SnehalCEO and CFOJul 28 '26Buy13.591,50020,3855,610,702Jul 30
Patel SnehalCEO and CFOJul 27 '26Buy13.621,50020,4305,609,202Jul 29
Patel SnehalCEO and CFOJul 24 '26Buy12.881,10014,1685,607,702Jul 27
Patel SnehalCEO and CFOJul 23 '26Buy13.142,50032,8505,606,602Jul 27
Patel SnehalCEO and CFOJan 13 '26Buy29.831,80053,6945,604,102Jan 15
Patel SnehalCEO and CFOJan 12 '26Buy27.542,90079,8665,602,302Jan 14
Patel SnehalCEO and CFODec 31 '25Buy21.364,30091,8485,599,402Jan 05
Patel SnehalCEO and CFODec 30 '25Buy21.732,90063,0175,595,102Jan 02
Patel SnehalCEO and CFODec 18 '25Buy12.624,10051,7425,592,202Dec 19
Patel SnehalCEO and CFONov 25 '25Buy8.374,60038,5025,588,102Nov 28
Patel SnehalCEO and CFONov 07 '25Buy8.4310,60089,3585,583,502Nov 12
Patel SnehalCEO and CFOOct 31 '25Buy9.262,30021,2985,572,902Nov 04
Patel SnehalCEO and CFOApr 25 '25Buy9.883,60035,5685,570,602Apr 29
Patel SnehalCEO and CFOApr 17 '25Buy8.985,40048,4925,567,002Apr 22
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.